1	CONTROLLED SUBSTANCES AMENDMENTS
2	2000 GENERAL SESSION
3	STATE OF UTAH
4	Sponsor: Ron Bigelow
5	AN ACT RELATING TO CRIMINAL LAW AND CONTROLLED SUBSTANCES;
6	AMENDING THE SCHEDULE OF CONTROLLED SUBSTANCES TO INCLUDE GHB;
7	SCHEDULING KETAMINE; AND CHANGING THE SCHEDULE OF ROHYPNOL.
8	This act affects sections of Utah Code Annotated 1953 as follows:
9	AMENDS:
10	58-37-4, as last amended by Chapter 283, Laws of Utah 1998
11	Be it enacted by the Legislature of the state of Utah:
12	Section 1. Section 58-37-4 is amended to read:
13	58-37-4. Schedules of controlled substances Schedules I through V Findings
14	required Specific substances included in schedules.
15	(1) There are established five schedules of controlled substances known as Schedules I,
16	II, III, IV, and V which shall consist of substances listed in this section.
17	(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the
18	official name, common or usual name, chemical name, or brand name designated:
19	(a) Schedule I:
20	(i) Unless specifically excepted or unless listed in another schedule, any of the following
21	opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when
22	the existence of the isomers, esters, ethers, and salts is possible within the specific chemical
23	designation:
24	(A) Acetyl-alpha-methylfentanyl
25	(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);
26	(B) Acetylmethadol;
27	(C) Allylprodine;

28	(D) Alphacetylmethadol, except levo-alphacetylmethadol also known as
29	levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;
30	(E) Alphameprodine;
31	(F) Alphamethadol;
32	(G) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
33	propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- propanilido) piperidine);
34	(H) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
35	piperidinyl]-N-phenylpropanamide);
36	(I) Benzethidine;
37	(J) Betacetylmethadol;
38	(K) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
39	piperidinyl]-N-phenylpropanamide);
40	(L) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
41	phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
42	(M) Betameprodine;
43	(N) Betamethadol;
44	(O) Betaprodine;
45	(P) Clonitazene;
46	(Q) Dextromoramide;
47	(R) Diampromide;
48	(S) Diethylthiambutene;
49	(T) Difenoxin;
50	(U) Dimenoxadol;
51	(V) Dimepheptanol;
52	(W) Dimethylthiambutene;
53	(X) Dioxaphetyl butyrate;
54	(Y) Dipipanone;
55	(Z) Ethylmethylthiambutene;
56	(AA) Etonitazene;
57	(BB) Etoxeridine;
58	(CC) Furethidine;

```
59
             (DD) Hydroxypethidine;
60
             (EE) Ketobemidone;
61
             (FF) Levomoramide;
             (GG) Levophenacylmorphan;
62
63
             (HH) Morpheridine;
64
             (II) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
65
             (JJ) Noracymethadol;
66
             (KK) Norlevorphanol;
67
             (LL) Normethadone;
68
             (MM) Norpipanone;
69
             (NN) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]
70
      propanamide;
71
             (OO) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
72
             (PP) Phenadoxone;
73
             (QQ) Phenampromide;
74
             (RR) Phenomorphan;
             (SS) Phenoperidine;
75
76
             (TT) Piritramide;
77
            (UU) Proheptazine;
78
             (VV) Properidine;
79
             (WW) Propiram;
80
             (XX) Racemoramide;
81
             (YY) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide;
82
             (ZZ) Tilidine;
83
             (AAA) Trimeperidine;
84
             (BBB) 3-methylfentanyl, including the optical and geometric isomers
85
      (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); and
             (CCC) 3-methylthiofentanyl
86
87
      (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide).
88
             (ii) Unless specifically excepted or unless listed in another schedule, any of the following
89
      opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts,
```

90	isomers, and salts of isomers is possible within the specific chemical designation:
91	(A) Acetorphine;
92	(B) Acetyldihydrocodeine;
93	(C) Benzylmorphine;
94	(D) Codeine methylbromide;
95	(E) Codeine-N-Oxide;
96	(F) Cyprenorphine;
97	(G) Desomorphine;
98	(H) Dihydromorphine;
99	(I) Drotebanol;
100	(J) Etorphine (except hydrochloride salt);
101	(K) Heroin;
102	(L) Hydromorphinol;
103	(M) Methyldesorphine;
104	(N) Methylhydromorphine;
105	(O) Morphine methylbromide;
106	(P) Morphine methylsulfonate;
107	(Q) Morphine-N-Oxide;
108	(R) Myrophine;
109	(S) Nicocodeine;
110	(T) Nicomorphine;
111	(U) Normorphine;
112	(V) Pholcodine; and
113	(W) Thebacon.
114	(iii) Unless specifically excepted or unless listed in another schedule, any material,
115	compound, mixture, or preparation which contains any quantity of the following hallucinogenic
116	substances, or which contains any of their salts, isomers, and salts of isomers when the existence
117	of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as
118	used in this Subsection (2)(iii) only, "isomer" includes the optical, position, and geometric isomers:
119	(A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
120	α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;

121	(B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
122	4-bromo-2,5-dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA;
123	(C) 4-bromo-2,5-dimethoxypenethylamine, some trade or other names:
124	2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
125	(D) 2,5-dimethoxyamphetamine, some trade or other names:
126	2,5-dimethoxy-α-methylphenethylamine; 2,5-DMA;
127	(E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
128	(F) 4-methoxyamphetamine, some trade or other names:
129	4-methoxy-α-methylphenethylamine; paramethoxyamphetamine, PMA;
130	(G) 5-methoxy-3,4-methylenedioxyamphetamine;
131	(H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
132	4-methyl-2,5-dimethoxy-α-methylphenethylamine; "DOM"; and "STP";
133	(I) 3,4-methylenedioxy amphetamine;
134	(J) 3,4-methylenedioxymethamphetamine (MDMA);
135	(K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-
136	alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
137	(L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
138	N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
139	(M) 3,4,5-trimethoxy amphetamine;
140	(N) Bufotenine, some trade and other names: 3-(β -Dimethylaminoethyl)-5-hydroxyindole
141	3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine;
142	mappine;
143	(O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
144	(P) Dimethyltryptamine, some trade or other names: DMT;
145	(Q) Ibogaine, some trade and other names:
146	7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
147	[5,4-b] indole; Tabernanthe iboga;
148	(R) Lysergic acid diethylamide;
149	(S) Marijuana;
150	(T) Mescaline;
151	(U) Parahexyl, some trade or other names:

152 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl; 153 (V) Peyote, meaning all parts of the plant presently classified botanically as Lophophora 154 williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such 155 plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, 156 its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12)); 157 (W) N-ethyl-3-piperidyl benzilate; 158 (X) N-methyl-3-piperidyl benzilate; 159 (Y) Psilocybin; 160 (Z) Psilocyn; 161 (AA) Tetrahydrocannabinols, synthetic equivalents of the substances contained in the 162 plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and 163 their isomers with similar chemical structure and pharmacological activity such as the following: 164 $\Delta 1$ cis or trans tetrahydrocannabinol, and their optical isomers $\Delta 6$ cis or trans 165 tetrahydrocannabinol, and their optical isomers $\Delta 3,4$ cis or trans tetrahydrocannabinol, and its 166 optical isomers, and since nomenclature of these substances is not internationally standardized, 167 compounds of these structures, regardless of numerical designation of atomic positions covered; 168 (BB) Ethylamine analog of phencyclidine, some trade or other names: 169 N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, 170 N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE; 171 (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 172 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP; 173 (DD) Thiophene analog of phencyclidine, some trade or other names: 174 1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and 175 (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy. 176 (iv) Unless specifically excepted or unless listed in another schedule, any material 177 compound, mixture, or preparation which contains any quantity of the following substances having 178 a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers 179 when the existence of the salts, isomers, and salts of isomers is possible within the specific 180 chemical designation: 181 (A) Flunitrazepam, trade name Rohypnol; 182 [(A)] (B) Mecloqualone; and

183	[(B)] (C) Methaqualone.	
184	(v) Any material, compound, mixture, or preparation containing any quantity of the	
185	following substances having a stimulant effect on the central nervous system, including their salts,	
186	isomers, and salts of isomers:	
187	(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or	
188	4,5-dihydro-5-phenyl-2-oxazolamine;	
189	(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone,	
190	alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;	
191	(C) Fenethylline;	
192	(D) Methcathinone, some other names: 2-(methylamino)-propiophenone;	
193	alpha-(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one;	
194	alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;	
195	methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of	
196	optical isomers;	
197	(E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);	
198	(F) N-ethylamphetamine; and	
199	(G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine;	
200	N,N-alpha-trimethylphenethylamine.	
201	(vi) Any material, compound, mixture, or preparation which contains any quantity of the	
202	following substances, including their optical isomers, salts, and salts of isomers, subject to	
203	temporary emergency scheduling:	
204	(A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and	
205	(B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).	
206	(vii) (A) Unless specifically excepted or unless listed in another schedule, any material,	
207	compound, mixture, or preparation which contains any quantity of gamma hydro butyrate or its	
208	analogs gamma butyrolactone and 1,4 butanediol.	
209	(B) As used in this Subsection 58-37-4(a)(vii), the analog gamma butyrolactone includes	
210	butyrolactone, 1,2 butanolide, 2-oxanolone, tetrahydro-2-furanone, dihydro-2(3H)-furanone and	
211	tetramethylene glycol, but does not include gamma aminobutric acid.	
212	(b) Schedule II:	

(i) Unless specifically excepted or unless listed in another schedule, any of the following

substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

- (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including:
- 220 (I) Raw opium;

214

215

216

217

218

219

236

237

238

239

240

241

242

243

- 221 (II) Opium extracts;
- 222 (III) Opium fluid;
- 223 (IV) Powdered opium;
- (V) Granulated opium;
- 225 (VI) Tincture of opium;
- (VII) Codeine;
- 227 (VIII) Ethylmorphine;
- 228 (IX) Etorphine hydrochloride;
- 229 (X) Hydrocodone;
- 230 (XI) Hydromorphone;
- 231 (XII) Metopon;
- 232 (XIII) Morphine;
- 233 (XIV) Oxycodone;
- 234 (XV) Oxymorphone; and
- 235 (XVI) Thebaine;
 - (B) Any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include the isoquinoline alkaloids of opium;
 - (C) Opium poppy and poppy straw;
 - (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation which is chemically equivalent or identical with any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, whether derived from the coca plant or synthetically produced, except the substances may not include decocainized coca leaves or extraction of coca leaves, which

245 extractions do not contain cocaine or ecgonine; and 246 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either 247 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy. 248 (ii) Unless specifically excepted or unless listed in another schedule, any of the following 249 opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when 250 the existence of the isomers, esters, ethers, and salts is possible within the specific chemical 251 designation, except dextrorphan and levopropoxyphene: (A) Alfentanil: 252 253 (B) Alphaprodine; 254 (C) Anileridine; 255 (D) Bezitramide; 256 (E) Bulk dextropropoxyphene (nondosage forms); 257 (F) Carfentanil: 258 (G) Dihydrocodeine; 259 (H) Diphenoxylate; 260 (I) Fentanyl; 261 (J) Isomethadone; 262 (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, 263 levomethadyl acetate, or LAAM; 264 (L) Levomethorphan; 265 (M) Levorphanol; 266 (N) Metazocine; 267 (O) Methadone; 268 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; 269 (O) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic 270 acid; 271 (R) Pethidine (meperidine); 272 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; 273 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate; 274 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;

275

(V) Phenazocine;

276	(W) Piminodine;
277	(X) Racemethorphan;
278	(Y) Racemorphan;
279	(Z) Remifentanil; and
280	(AA) Sufentanil.
281	(iii) Unless specifically excepted or unless listed in another schedule, any material,
282	compound, mixture, or preparation which contains any quantity of the following substances having
283	a stimulant effect on the central nervous system:
284	(A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
285	(B) Methamphetamine, its salts, isomers, and salts of its isomers;
286	(C) Phenmetrazine and its salts; and
287	(D) Methylphenidate.
288	(iv) Unless specifically excepted or unless listed in another schedule, any material,
289	compound, mixture, or preparation which contains any quantity of the following substances having
290	a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers
291	when the existence of the salts, isomers, and salts of isomers is possible within the specific
292	chemical designation:
293	(A) Amobarbital;
294	(B) Glutethimide;
295	(C) Pentobarbital;
296	(D) Phencyclidine;
297	(E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
298	1-piperidinocyclohexanecarbonitrile (PCC); and
299	(F) Secobarbital.
300	(v) Unless specifically excepted or unless listed in another schedule, any material,
301	compound, mixture, or preparation which contains any quantity of Phenylacetone.
302	Some of these substances may be known by trade or other names: phenyl-2-propanone,
303	P2P; benzyl methyl ketone, methyl benzyl ketone.
304	(vi) (A) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in
305	a U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
306	(6aR-trans)-6a.7.8.10a-tetrahydro-6.6.9-trimethyl-3-pentyl-6H-dibenzo[b.d]pyran-1-ol, or

307	(-)-delta-9-(trans)-tetrahydrocannabinol; and
308	(B) Nabilone, another name for nabilone:
309	$(\pm)\text{-trans-3-}(1,1\text{-dimethylheptyl})\text{-}6,6a,7,8,10,10a\text{-hexahydro-1-hydroxy-6},$
310	6-dimethyl-9H-dibenzo[b,d]pyran-9-one.
311	(c) Schedule III:
312	(i) Unless specifically excepted or unless listed in another schedule, any material,
313	compound, mixture, or preparation which contains any quantity of the following substances having
314	a stimulant effect on the central nervous system, including its salts, isomers whether optical,
315	position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts
316	of isomers is possible within the specific chemical designation:
317	(A) Those compounds, mixtures, or preparations in dosage unit form containing any
318	stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed
319	on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of
320	Federal Regulations, and any other drug of the quantitive composition shown in that list for those
321	drugs or which is the same except that it contains a lesser quantity of controlled substances;
322	(B) Benzphetamine;
323	(C) Chlorphentermine;
324	(D) Clortermine; and
325	(E) Phendimetrazine.
326	(ii) Unless specifically excepted or unless listed in another schedule, any material,
327	compound, mixture, or preparation which contains any quantity of the following substances having
328	a depressant effect on the central nervous system:
329	(A) Any compound, mixture, or preparation containing amobarbital, secobarbital,
330	pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which
331	are not listed in any schedule;
332	(B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital,
333	or any salt of any of these drugs which is approved by the Food and Drug Administration for
334	marketing only as a suppository;
335	(C) Any substance which contains any quantity of a derivative of barbituric acid or any salt
336	of any of them:

337

(D) Chlorhexadol;

338	(E) Ketamine;
339	[(E)] <u>(F)</u> Lysergic acid;
340	[(F)] <u>(G)</u> Lysergic acid amide;
341	[(G)] (H) Methyprylon;
342	[(H)] (I) Sulfondiethylmethane;
343	[(1)] (J) Sulfonethylmethane;
344	[H] (K) Sulfonmethane; and
345	[(K)] (L) Tiletamine and zolazepam or any of their salts, some trade or other names for
346	a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
347	2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
348	4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
349	flupyrazapon.
350	(iii) Nalorphine.
351	(iv) Unless specifically excepted or unless listed in another schedule, any material,
352	compound, mixture, or preparation containing limited quantities of any of the following narcotic
353	drugs, or their salts calculated as the free anhydrous base or alkaloid:
354	(A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams
355	per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
356	(B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams
357	per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic
358	amounts;
359	(C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
360	than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid
361	of opium;
362	(D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
363	than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
364	recognized therapeutic amounts;
365	(E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
366	milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
367	therapeutic amounts;

(F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than

369 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized 370 therapeutic amounts; 371 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not 372 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in 373 recognized therapeutic amounts; 374 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with 375 one or more active, non-narcotic ingredients in recognized therapeutic amounts. 376 (v) Unless specifically excepted or unless listed in another schedule, anabolic steroids 377 including any of the following or any isomer, ester, salt, or derivative of the following that 378 promotes muscle growth: 379 (A) Boldenone; 380 (B) Chlorotestosterone (4-chlortestosterone); 381 (C) Clostebol; 382 (D) Dehydrochlormethyltestosterone; 383 (E) Dihydrotestosterone (4-dihydrotestosterone); 384 (F) Drostanolone; 385 (G) Ethylestrenol; 386 (H) Fluoxymesterone; 387 (I) Formebulone (formebolone); 388 (J) Mesterolone; 389 (K) Methandienone; 390 (L) Methandranone; 391 (M) Methandriol; 392 (N) Methandrostenolone; 393 (O) Methenolone; 394 (P) Methyltestosterone; 395 (Q) Mibolerone; 396 (R) Nandrolone; 397 (S) Norethandrolone;

398

399

(T) Oxandrolone;

(U) Oxymesterone;

400	(V) Oxymetholone;
401	(W) Stanolone;
402	(X) Stanozolol;
403	(Y) Testolactone;
404	(Z) Testosterone; and
405	(AA) Trenbolone.
406	Anabolic steroids expressly intended for administration through implants to cattle or other
407	nonhuman species, and approved by the Secretary of Health and Human Services for use, may not
408	be classified as a controlled substance.
409	(d) Schedule IV:
410	(i) Unless specifically excepted or unless listed in another schedule, any material,
411	compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less
412	than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them;
413	(ii) Unless specifically excepted or unless listed in another schedule, any material,
414	compound, mixture, or preparation which contains any quantity of the following substances,
415	including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts
416	of isomers is possible within the specific chemical designation:
417	(A) Alprazolam;
418	(B) Barbital;
419	(C) Bromazepam;
420	(D) Butorphanol;
421	(E) Camazepam;
422	(F) Chloral betaine;
423	(G) Chloral hydrate;
424	(H) Chlordiazepoxide;
425	(I) Clobazam;
426	(J) Clonazepam;
427	(K) Clorazepate;
428	(L) Clotiazepam;
429	(M) Cloxazolam;
430	(N) Delorazepam;

431	(O) Diazepam;
432	(P) Estazolam;
433	(Q) Ethchlorvynol;
434	(R) Ethinamate;
435	(S) Ethyl loflazepate;
436	(T) Fludiazepam;
437	[(U) Flunitrazepam;]
438	[(V)] <u>(U)</u> Flurazepam;
439	[(W)] <u>(V)</u> Halazepam;
440	[(X)] (W) Haloxazolam;
441	[(Y)] (X) Ketazolam;
442	[(Z)] (Y) Loprazolam;
443	[(AA)] (Z) Lorazepam;
444	[(BB)] (AA) Lormetazepam;
445	[(CC)] (BB) Mebutamate;
446	[(DD)] <u>(CC)</u> Medazepam;
447	[(EE)] (DD) Meprobamate;
448	[(FF)] (EE) Methohexital;
449	[(GG)] (FF) Methylphenobarbital (mephobarbital);
450	[(HH)] (GG) Midazolam;
451	[(H)] (HH) Nimetazepam;
452	[(JJ)] <u>(II)</u> Nitrazepam;
453	[(KK)] (JJ) Nordiazepam;
454	[(LL)] (KK) Oxazepam;
455	[(MM)] <u>(LL)</u> Oxazolam;
456	[(NN)] (MM) Paraldehyde;
457	[(OO)] (NN) Pentazocine;
458	[(PP)] (OO) Petrichloral;
459	[(QQ)] <u>(PP)</u> Phenobarbital;
460	[(RR)] (QQ) Pinazepam;
461	[(SS)] (RR) Prazepam:

462 [(TT)] (SS) Quazepam; 463 [(UU)] (TT) Temazepam; 464 [(VV)] (UU) Tetrazepam; 465 [(WW)] (VV) Triazolam; and [(XX)] (WW) Zolpidem. 466 467 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains any quantity of the following substances, including its salts, isomers whether optical, position, or 468 469 geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers 470 is possible. 471 (iv) Unless specifically excepted or unless listed in another schedule, any material, 472 compound, mixture, or preparation which contains any quantity of the following substances having 473 a stimulant effect on the central nervous system, including its salts, isomers whether optical, 474 position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, 475 and salts of isomers is possible within the specific chemical designation: 476 (A) Cathine ((+)-norpseudoephedrine); 477 (B) Diethylpropion; 478 (C) Fencamfamine; 479 (D) Fenproprex; 480 (E) Mazindol; 481 (F) Mefenorex; 482 (G) Pemoline, including organometallic complexes and chelates thereof; 483 (H) Phentermine; 484 (I) Pipradrol; and (J)SPA ((-)-1-dimethylamino-1,2-diphenylethane). 485 486 (v) Unless specifically excepted or unless listed in another schedule, any material, 487 compound, mixture, or preparation which contains any quantity of dextropropoxyphene 488 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts. 489 (e) Schedule V: Any compound, mixture, or preparation containing any of the following 490 limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, 491 which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to 492 confer upon the compound, mixture, or preparation valuable medicinal qualities other than those

493 possessed by the narcotic drug alone: 494 (i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams; 495 (ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams; 496 (iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams; 497 (iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of 498 atropine sulfate per dosage unit; 499 (v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; 500 (vi) not more than 0.5 milligram of different and not less than 25 micrograms of atropine 501 sulfate per dosage unit;

(vii) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers; and

(viii) unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any Buprenorphine and its salts.

Legislative Review Note as of 12-3-99 2:19 PM

01-19-00 2:09 PM

502

503

504

505

506

A limited legal review of this legislation raises no obvious constitutional or statutory concerns.

Office of Legislative Research and General Counsel

H.B. 77